New Year, New Horizons: Discover Why Meliá Ho Tram Beach Resort is the Ultimate Getaway

New Year, New Horizons: Discover Why Meliá Ho Tram Beach Resort is the Ultimate Getaway

VUNG TAU, Vietnam, Jan. 22, 2025 /PRNewswire/ -- Now that the new year is here, it's the perfect time to plan your next escape to Melia Ho Tram Beach Resort, a top destination for those seeking a mix of luxury, natural beauty, and vibrant...

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across North America, Asia, Europe and the Middle East NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced...

Discover Vietnam's Hidden Gem: Coastal Retreats at Meliá Ho Tram Beach Resort

Discover Vietnam's Hidden Gem: Coastal Retreats at Meliá Ho Tram Beach Resort

VUNG TAU, Vietnam, Dec. 26, 2024 /PRNewswire/ -- Melia Ho Tram Beach Resort, a premier beach destination in Vietnam, invites international visitors to experience an unforgettable vacation this holiday season. Located just a 2-hour drive from Ho Chi...

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

ROCKVILLE, Md. and SUZHOU, China, Nov. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for...

NEW STRATEGY NEW TECHNOLOGY : FOTON BRAND REJUVENATION & ALL-NEW PRODUCTS LAUNCH

NEW STRATEGY NEW TECHNOLOGY : FOTON BRAND REJUVENATION & ALL-NEW PRODUCTS LAUNCH

BEIJING, Oct. 12, 2023 /PRNewswire/ -- On October 11th, FOTON held its global BRAND REJUVENATION & ALL-NEW PRODUCTS LAUNCH event in Changsha, China. 63 Distributors, customers and media representing 22 countries worldwide came together to...

menu
menu